TeraRecon Joins ConcertAI Family to Streamline SaaS Research and Bolster RWE Studies

ConcertAI reported the addition of TeraRecon to its portfolio in an agreement intended to support clinical decision-making. The software-as-a-service (SaaS) company will bring expertise in real world data (RWD), including electronic health records and genomic data, and support high-level clinical research and regulatory submissions.

ConcertAI CEO Jeff Elton remarks, “With the FDA’s recent guidance on RWD for regulatory decision-making, ConcertAI is the only oncology, hematology, and urology-focused company capable of integrating primary data sources for the critical assessment of patient response and safety,” adding, “It is anticipated that 100% of regulatory submissions in oncology will integrate real-world evidence [RWE].” Read more here.

(Source: ConcertAI, 11/9/21)